Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Genome-Wide In Vivo CRISPR Screens in Human T Cells Identify GPCR Pathway Targets to Enhance CAR-T Therapies for Solid Tumors

Award Number: R01CA309039
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2026
PERIOD OF PERFORMANCE END DATE: 03/31/2031

Group Awards By:

View Award Description

Genome-Wide In Vivo CRISPR Screens in Human T Cells Identify GPCR Pathway Targets to Enhance CAR-T Therapies for Solid Tumors - Background: T cell therapies have been transformative for certain leukemias and lymphomas, however solid tumors have proven far more difficult due to challenges such as poor infiltration, harsh metabolic environments, and a myriad of suppressive factors in the tumor microenvironment (TME). Most large-scale genetic screens in human T cells have been performed in vitro, which fail to capture many solid tumor-specific barriers. However, performing large-scale screens in vivo has been impractical due to the low recovery of T cells from tumors, which significantly limits screening throughput. To overcome these limitations, we developed a novel screening platform that allows engagement of human CD4+ and CD8+ T cells with any polyclonal repertoire and achieves significantly higher T cell recovery from tumors, enabling genome-wide screens in relatively few mice. Preliminary Data: Using this system, we performed two genome-wide CRISPR loss-of-function screens for gene targets that enhance T cell abundance within tumors as well as effector function in tumors based on interferon- γ production. We uncovered many genes with known roles in T cell fitness, as well as many novel gene targets, including from two GPCR signaling pathways that regulate (1) T cell resistance to TME-mediated suppression and (2) T cell trafficking and infiltration into tumors. The PTGER4-GNAS (Gαs) signaling pathway was enriched in our screens and has been previously shown to induce dysfunction in mouse T cells in the TME in response to suppressive cues. Our preliminary data suggest knocking out GNAS in human T cell therapies can robustly enhance tumor control and survival. Our screens and preliminary validation data also identified P2RY8-Gα13 signaling, a pathway previously characterized in B cell migration, as a major regulator of human T cell trafficking into tumors. Research Strategy: In Aim 1, we will investigate the genetic disruption of GPCR-Gαs-PKA signaling to enhance T cell resistance to TME suppression. We will test the efficacy of GNAS KO in TCR- and CAR-T cells in multiple solid tumor models and we will dissect the dominant upstream GPCRs as well as key downstream PKA targets driving these effects. In Aim 2, we will establish the P2RY8-Gα13 GPCR signaling pathway as a novel regulator of T cell trafficking and immune exclusion. We will use a combination of in vivo and in vitro competition assays to assess how this pathway affects T cell migration into tumors, as well as functional genetics and microscopy approaches to evaluate its role in immune exclusion. We will test whether the P2RY8 ligand, S-geranylgeranyl-L-glutathione, is a repulsive cue used by tumors to block T cell infiltration. In both aims, in addition to our studies in healthy T cells, we will test the relevance of these pathways in tumor- infiltrating lymphocytes from solid tumor patients. Expected Results and Impact: These studies will rigorously test whether targeting key GPCR signaling pathways nominated by our screens can enhance T cell infiltration and durable effector function. Our findings will provide novel strategies for engineering more effective T cell therapies for solid tumors and establish a new standard for in vivo functional genomics screens in human T cells.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $680,597 )
2026	2026	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Cancer Biology Research	000	1	3/25/2026	NEW	$680,597
														Subtotal = $680,597

Grand Total All Awards = $680,597

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Genome-Wide In Vivo CRISPR Screens in Human T Cells Identify GPCR Pathway Targets to Enhance CAR-T Therapies for Solid Tumors

Award Number: R01CA309039

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2026

PERIOD OF PERFORMANCE END DATE: 03/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer